Dunhill Financial’s NovoCure NVCR Stock Holding History

Dunhill Financial’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32	Hold	2	–	–	﹤0.01%	1562
2026 Q1	$23	Hold	2	–	–	﹤0.01%	1750
2025 Q4	$28	Buy	+2	New	+$26	﹤0.01%	1839

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Dunhill Financial's NVCR Position: Q2 2026 in Review

Dunhill Financial held its NovoCure (NVCR) position steady in Q2 2026 at 2 shares worth $32. The position accounts for ﹤0.01% of the portfolio, ranked #1562.

Dunhill Financial first reported a position in NVCR in Q4 2025 and has held it in 3 quarters since. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Dunhill Financial held 2 shares of NovoCure worth $32 as of Q2 2026.
Dunhill Financial left its NovoCure share count unchanged in Q2 2026.
NovoCure made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1562 holding.
Dunhill Financial first reported a position in NovoCure in Q4 2025 and has held it in 3 quarters since.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.